Of the 70,000 new cases of non-Hodgkin?s lymphoma (NHL) diagnosed in 2014, the most common subtype is diffuse large B-cell lymphoma (DLBCL), of these approximately 40% will relapse after standard induction with CHOP-R. Of these patients, the only opportunity for long-term disease control is with CAR T cell therapy, autologous or allogeneic transplant. Many patients are not candidates due to age or co-morbidities, cannot achieve required disease control, or do not have a suitable donor. Additionally, many relapsed indolent and mantle cell lymphoma (MCL) patients eventually exhaust all treatment options are not candidates for aggressive cytotoxic chemotherapy due to co-morbidities or the potential for substantial myelosuppression. Patients with relapsed/refractory (R/R) NHL clearly represent an unmet medical need. Both lenalidomide and blinatumomab have proven, but limited, efficacy in R/R NHL. Lenalidomide has been shown to modulate different components of the immune system by altering cytokine production, regulating T cell co-stimulation and augmenting the NK cell cytotoxicity. Blinatumomab specifically targets the CD19 antigen present on B cells. The inability of blinatumomab to mediate responses or durable responses is likely due to the inability to recruit competent cytotoxic T cells or eventual T cell exhaustion. The current approach will mediate redirection of lenalidomide-mediated, activated, competent, cytotoxic T cells to the malignant CD19+ B cells. UC Davis protocol # PHI-79 (NCI protocol # 9924, Clinicaltrials.gov identifier NCT02568553) examines the relationship between blinatumomab-, or lenalidomide + blinatumomab-mediated T cell activation and response. The phase I portion of the study has been completed and demonstrated the combination was well tolerated with an encouraging ORR of 90% (Poh et al ASH 2019). We are seeking supplemental funds to conduct the ancillary studies associated with this trial, studies which are directly in line with the goals of the City of Hope and UC Davis Comprehensive Cancer Center UM1 grant. Using biospecimens collected from PHI-79, we aim to identify biomarkers for therapeutic response. Our team has extensive experience integrating omic data sets to develop multi-analyte classifiers (biomarkers) for clinical diagnostic tests and have developed computational tools to streamline these efforts. Our specific hypothesis is that composite biomarkers comprised of easily quantifiable immune response elements will be able to predict a patient?s ultimate responsiveness to therapy.

Public Health Relevance

Using specimens collected from patients with relapsed or refractory non-Hodgkin?s lymphoma treated with lenalidomide and blinatumomab, our goal for the supplement application is to identify biomarkers for treatment response. Accrual completion is expected in a few months with all samples ready for analysis at the time of funding. Through predictive biomarkers, researchers can potentially classify patients who benefit from therapy, reduce treatment costs, or prevent life-threatening treatment-related adverse events.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
3UM1CA186717-06S1
Application #
10192396
Study Section
Program Officer
Ivy, S Percy
Project Start
2020-06-15
Project End
2023-02-28
Budget Start
2020-06-15
Budget End
2023-02-28
Support Year
6
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Beckman Research Institute/City of Hope
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Liu, Stephen V; Groshen, Susan G; Kelly, Karen et al. (2018) A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors. Cancer Chemother Pharmacol 82:723-732
El-Khoueiry, Anthony B; O'Donnell, Robert; Semrad, Thomas J et al. (2018) A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 81:957-963
Kirschbaum, Mark H; Frankel, Paul; Synold, Timothy W et al. (2018) A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study. Br J Haematol 180:445-448
Tarhini, Ahmad A; Frankel, Paul; Ruel, Christopher et al. (2018) NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma. Cancer 124:4332-4341
Pili, Roberto; Quinn, David I; Hammers, Hans J et al. (2017) Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870). Clin Cancer Res 23:7199-7208
Goncalves, Priscila H; Heilbrun, Lance K; Barrett, Michael T et al. (2017) A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. Oncotarget 8:32918-32929
Dorff, Tanya B; Longmate, Jeff A; Pal, Sumanta K et al. (2017) Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. Cancer 123:4566-4573
Mohrbacher, Ann M; Yang, Allen S; Groshen, Susan et al. (2017) Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial. Clin Cancer Res 23:4550-4555
Connolly, Roisin M; Li, Huili; Jankowitz, Rachel C et al. (2017) Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. Clin Cancer Res 23:2691-2701
Azad, Nilofer S; El-Khoueiry, Anthony; Yin, Jun et al. (2017) Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study. Oncotarget 8:35326-35338

Showing the most recent 10 out of 23 publications